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Abstract
Background: Silica particles cationized by dioctadecyldimethylammonium bromide (DODAB)
bilayer were previously described. This work shows the efficiency of these particulates for antigen
adsorption and presentation to the immune system and proves the concept that silica-based
cationic bilayers exhibit better performance than alum regarding colloid stability and cellular
immune responses for vaccine design.
Results: Firstly, the silica/DODAB assembly was characterized at 1 mM NaCl, pH 6.3 or 5 mM
Tris.HCl, pH 7.4 and 0.1 mg/ml silica over a range of DODAB concentrations (0.001–1 mM) by
means of dynamic light scattering for particle sizing and zeta-potential analysis. 0.05 mM DODAB
is enough to produce cationic bilayer-covered particles with good colloid stability. Secondly,
conditions for maximal adsorption of bovine serum albumin (BSA) or a recombinant, heat-shock
protein from Mycobacterium leprae (18 kDa-hsp) onto DODAB-covered or onto bare silica were
determined. At maximal antigen adsorption, cellular immune responses in vivo from delayed-type
hypersensitivity reactions determined by foot-pad swelling tests (DTH) and cytokines analysis
evidenced the superior performance of the silica/DODAB adjuvant as compared to alum or
antigens alone whereas humoral response from IgG in serum was equal to the one elicited by alum
as adjuvant.
Conclusion: Cationized silica is a biocompatible, inexpensive, easily prepared and possibly general
immunoadjuvant for antigen presentation which displays higher colloid stability than alum, better
performance regarding cellular immune responses and employs very low, micromolar doses of
cationic and toxic synthetic lipid.
Background
Over the last two decades novel assemblies obtained from
particles and lipids have been introduced as important
tools to novel applications in drug and vaccine delivery
[1-4]. Particulates such as silica, latex or hydrophobic
drugs have been coated by lipids and successfully
employed in biomolecular recognition [5,6] drug delivery
[7,8] and antigen presentation [9,10]. The systematic and
quantitative evaluation of particle-lipid interaction has
been realized by means of adsorption isotherms of lipids
on particles, effects of lipids on particle size and zeta-
potential from dynamic light scattering methods and
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determination of colloid stability from turbidity kinetics
or particle sedimentation over time [1-10]. Cationic lip-
ids, in particular, are especially interesting to cover parti-
cles, since cationic particles may electrostatically combine
with a vast variety of oppositely charged biomolecules,
cells or other biological structures. Cationization, in gen-
eral, has often been explored as a convenient approach to
target active biomolecules into cells [11].
The control of lipid assembly on particles turned out to be
dependent on properties of the intervening medium, eg
ionic strength, and on the proportion of surface areas for
bilayer vesicles and particles in dispersion [12-15]. From
equivalence of total surface areas for particles and cationic
lipid bilayers, over a range of low ionic strength, a good
colloid stability was reported for the bilayer-covered cati-
onic particles [3,4,12,15].
In this work, the interaction between silica previously
coated with cationic bilayers of dioctadecyldimethylam-
monium bromide (DODAB) [15] and the model protein
bovine serum albumin (BSA) is investigated aiming at
antigen presentation to the immune system by silica-
based cationized particles. BSA choice was due to various
reasons: its extensively studied adsorption behaviour at
interfaces [16,17]; its utility to prevent nonspecific bind-
ing in biosensing and proteomics applications [17-19], its
conformational adaptability as a "soft" globular protein
[20], its thoroughly investigated adsorption onto hydro-
phobic or hydrophilic particles sometimes resulting in
exchange between the adsorbed and dissolved states [21-
24] and its substantial adsorption onto cationic and large
DODAB vesicles [25].
The 18 kDa-hsp protein belongs to a conserved protein
family of M. leprae heat-shock proteins that display pro-
nounced immunogenicity and are considered important
targets of the immunoresponse to mycobacteria and, as
such, relevant to subunit vaccine design. Peripheral blood
mononuclear cells and T-cell lines from M. leprae vacci-
nated subjects proliferated in response to this protein
[26]. Furthermore, overexpression and scaling-up of 18
kDa-hsp production in Saccharomyces cerevisae has already
been described so that this protein is available in suffi-
cient amount for a complete physico-chemical study of
the adjuvant-antigen interaction [27-29].
The DODAB cationic lipid and its assemblies in water dis-
persion have been established as effective immunoadju-
vants able to stimulate dendritic cells and often employed
to present antigens [29-34]. Silica particles are biocompat-
ible, represent a reference adsorbent, offer a chemically
well defined surface and are widely used as a chromato-
graphic stationary phase [34,35].
We have recently combined the typical property of parti-
cles that stimulate dendritic cells uptake with the adjuvant
effect of DODAB by using supported DODAB bilayers on
latex to present antigens [9]. Here we take advantage of
the biocompatible character of silica [35,36] to produce
DODAB-covered silica particles for further immobiliza-
tion and presentation of two different model antigens:
BSA and 18 kDa-hsp protein.
Results and discussion
Coverage of silica particles with a cationic bilayer and BSA 
adsorption
Charge density on silica particles increases with pH and
ionic strength [37] so that electrostatic attraction between
DODAB bilayer and silica is substantial over the 1–10 mM
range of monovalent salt concentration, and leads to
DODAB bilayer deposition onto particles [15]. One
should notice that poor or none DODAB adsorption on
silica was previously reported for pure water as interven-
ing media [13-15,38]. Therefore, the experiments in this
work were designed either at 1 or at 5 mM monovalent
salt.
The DODAB bilayer in closed vesicles is in the rigid gel
state at room temperature. This represents an important
limitation regarding deposition of bilayers onto particles
hampering the occurrence of vesicle disruption which is
essential for bilayer deposition. We have previously
shown that closed vesicles with bilayers in the gel state do
not disrupt upon contact with silica particles [38], thus, in
this work, bilayer deposition on silica is obtained by
employing disrupted vesicles or bilayer fragments.
Both at 1 mM NaCl, pH 6.3, and at 5.0 mM Tris.HCl, pH
7.4, the dependence of size and zeta-potential of silica
particles on DODAB concentration shows size minimiza-
tion and zeta-potential maximization at and above 0.050
mM DODAB (Figure 1). Therefore, 0.050 mM DODAB
was the final concentration selected to cover silica parti-
cles at 0.1 mg/ml with one DODAB bilayer. Theoretically,
assuming 0.6 nm2 as the DODAB area per molecule at the
air-water interface and 26–50 m2/g as silica specific sur-
face area, the DODAB concentration required to cover sil-
ica particles at 0.1 mg/ml with one bilayer would be
0.014–0.028 mM DODAB, in reasonable agreement with
the 0.050 mM DODAB experimentally determined for
minimization of particle size and maximal zeta-potential
(Figure 1). The bell-shaped dependence of zeta-average
diameter of particles as a function of the logarithm of
DODAB concentration shows the occurrence of two
regions of high colloidal stability identified by low sizes
and large zeta-potentials in modulus: one at negative and
the other at positive zeta-potentials both at mean sizes
similar to the one of bare silica and over a range of low
and high DODAB concentrations (Figure 1).BMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
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The stability of the silica/DODAB system was sistemati-
cally described in a previous work [15]. The adjuvant sys-
tem is very reproducible yielding always the same mean
Dz and zeta-potential for the same final silica and
DODAB concentrations. However, upon antigen addi-
tion, zeta-potential may decrease to values close to zero so
that colloid stability will be low.
Table 1 shows the detailed physical description of silica,
DODAB bilayer fragments (BF), silica/DODAB and silica/
DODAB/BSA regarding mean particle size, zeta-potential
and polydispersity. In agreement with Tadros and
Lyklema data [37], silica in 1 mM NaCl at pH 6.3 was less
charged (zeta-potential of -40 mV) than at pH 7.4 (zeta-
potential of -47 mV). One should notice the aggregated
state of BSA in solution and the large polydispersity of
these aggregates at 0.5 mg/ml in 1 mM NaCl and pH 6.3
or in 5 mM Tris.HCl, pH 7.4 (Table 1). Consistently, at pH
7.4, the protein aggregates display a more negative zeta-
potential than the one at pH 6.3, as expected from BSA
isoelectric point at pH 5.0–5.5. When the protein was
added to silica/DODAB particles to a final [BSA] of 0.025
The concentration of cationic lipid DODAB required to cover silica particles with a cationic lipid bilayer is 0.05 mM Figure 1
The concentration of cationic lipid DODAB required to cover silica particles with a cationic lipid bilayer is 0.05 
mM. Effect of DODAB concentration on zeta-average diameter (A, C) and zeta-potential (B, D) of SiO2 particles at 0.1 mg sil-
ica/ml, 25°C, in 1 mM NaCl, pH 6.3 (A, B) or 5 mM Tris.HCl, pH 7.4 (C, D). Cationic bilayer fragments were adsorbed onto 
0.1 mg/ml silica particles (AEROSIL OX-50). Measurements were performed after 1 h interaction. The arrows indicate 0.05 
mM DODAB as the concentration of cationic lipid that is required to attain maximal positive zeta-potential and minimal sizes 
for particles in dispersion.BMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
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mg/ml, different assemblies were obtained at pH 6.3 and
7.4 (Table 1): the larger electrostatic attraction at pH 7.4
drove BSA onto particles to yield a slightly negatively
charged particle whereas, at pH 6.3, the moderate electro-
static attraction, moderately drove BSA onto particles
yielding a still positively charged particle with 24 mV of
zeta-potential (Table 1). The design chosen for evaluation
of BSA presentation to the immune system was the one in
5 mM Tris.HCl, pH 7.4 yielding mean diameters of ca. 800
nm. All other results in Table 1, consistently agreed with
previous data published by our group.
Figure 2 shows size distributions for silica, DODAB BF
and silica/DODAB for each dispersion both at 1 mM
NaCl, pH 6.3 and at 5 mM Tris. HCl, pH 7.4. Under both
experimental conditions, DODAB addition produced the
silica-based positively charged particles with final size dis-
tributions similar to the ones of bare silica. Quantification
of BSA amount adsorbed from solution onto bare silica
(Figure 3) or onto silica/DODAB (Figure 4) in the two
quoted intervening media was carried out over a range of
added BSA concentrations (0–150 μg/ml). Given the lang-
muirian profile of the adsorption isotherms, we applied
the Langmuir model in order to linearize adsorption iso-
therms and obtain adsorption parameters prone to be
compared with each other for different intervening media
and silica or silica/DODAB as adsorbates. Table 2 summa-
rizes the BSA adsorption parameters such as maximal
adsorption and affinity constant for adsorption onto bare
silica or onto silica/DODAB particles in the two different
intervening media. BSA adsorbs with the highest affinity
onto bare silica, possibly driven by several hydrogen
bonds between silanoils on particles and carbonyls on the
protein, but maximal adsorption is at lowest indicating
Table 1: Physical properties of SiO2, DODAB BF dispersion, BSA, 18 kDa-hsp leprae and their mixtures in 1 mM NaCl (pH 6.3) or in 5 
mM TrisHCl (pH 7.4)
Dispersion SiO2
(mg/ml)
DODAB
(mM)
Protein
(mg/ml)
Mean Diameter
(nm)
Zeta Potencial
(mV)
Polydispersity
(Index)
SiO2
(i) 0.1 - - 328 ± 7 -40 ± 2 0.240 ± 0.01
DODAB(i) - 1.0 - 67 ± 1 41 ± 3 0.120 ± 0.04
BSA(i) - - 0.5 25 ± 4 -28 ± 1 0.450 ± 0.09
DODAB/BSA(i) - 0.1 0.500 72 ± 1 3 ± 1 0.245 ± 0.01
SiO2/DODAB(i) 0.1 0.05 - 304 ± 2 32 ± 1 0.260 ± 0.02
SiO2/DODAB/BSA(i) 0.1 0.05 0.025 324 ± 8 24 ± 1 0.301 ± 0.01
SiO2
(ii) 0.1 - - 294 ± 2 -47 ± 2 0.180 ± 0.02
DODAB(ii) - 1.0 1.0 74 ± 1 33 ± 5 0.270 ± 0.04
BSA(ii) - - 0.5 24 ± 1 -58 ± 18 0.397 ± 0.01
SiO2/DODAB(ii) 0.1 0.05 - 373 ± 7 33 ± 2 0.260 ± 0.02
SiO2/DODAB/BSA(ii) 0.1 0.05 0.025 851 ± 36 -1.3 ± 4 0.396 ± 0.03
18 kDa-hsp M. leprae(i) - - 0.5 732 ± 188 -29 ± 2 0.35 ± 0.05
DODAB/18 kDa-hsp(i) - 0.1 0.05 208 ± 8 39 ± 5 0.315 ± 0.01
18 kDa-hsp M. leprae(ii) - - 0.05 360 ± 16 -43 ± 18 0.180 ± 0.09
SiO2/DODAB/18 kDa-hsp(ii) 0.1 0.05 0.05 2132 ± 370 -2 ± 2 0.492 ± 0.04
Al(OH3)(i) - - - 458 ± 3 28 ± 3 0.191 ± 0.04
Al(OH3)(ii) - - - 702 ± 17 14 ± 2 0.317 ± 0.01
Al(OH3)/18 kDa-hsp(i),(iii) - - 0.05 4888 ± 665 - 0.272 ± 0.07
Al(OH3)/18 kDa-hsp(ii),(iii) - - 0.05 10607 ± 2998 - 0.480 ± 0.03
(i) 1 mM NaCl (pH 6.3). (ii) 5 mM Tris-HCl (pH 7.4). (iii) Al(OH3) at 0.1 mg/ml.
Table 2: Maximal adsorption, affinity constant (K) and area per adsorbed BSA molecule on silica (0.1 mg/ml) or on DODAB covered 
silica particles in two different media
Particles Maximal adsorption
(molecules m-2)
Affinity Constant
(K, M-1)
Area per adsorbed molecule
(nm2)
SiO2/BSA(i) 4.14 × 1016 1.19 × 109 24.15
SiO2/BSA(ii) 4.75 × 1016 8.19 × 107 21.05
SiO2/DODAB/BSA(i) 7.20 × 1016 5.18 × 107 13.88
SiO2/DODAB/BSA(ii) 3.22 × 1017 8.98 × 108 3.10
SiO2/18 kDa-hsp(ii) 1.12 × 1017 --
SiO2/DODAB/18 kDa-hsp(ii) 10.00 × 1017 --
(i) 1 mM NaCl (pH 6.3).
(ii) 5 mM Tris.HCl (pH 7.4).
Final DODAB concentration was 0.05 mM.BMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
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the largest area per BSA molecule occupied at maximal
adsorption among those in all media and adsorbates
tested (Table 2). Changing the medium to 5 mM Tris.HCl
and pH 7.4, diminished BSA affinity for the negatively
charged bare silica since electrostatic repulsion was
increased by increasing negative charge on the protein
though maximal adsorption remained approximately the
same (Table 2). Offering the DODAB bilayer on silica to
the protein improved BSA maximal adsorption for both
intervening media. However, a large increase in the affin-
ity constant such as the one obtained for BSA adsorption
on silica/DODAB in Tris.HCl pH 7.4 (Table 2) may not be
so desirable in terms of molecular order of BSA on the par-
ticle surface. While BSA appeared to be in a ordered end-
on position occupying about 14 nm2 at maximal adsorp-
tion (Table 2) under conditions of moderate electrostatic
attraction between BSA and silica/DODAB (1 mM NaCl,
pH 6.3) further increasing this attraction drove massive
Comparison of size distributions and zeta-potentials for silica and silica-based cationic bilayers Figure 2
Comparison of size distributions and zeta-potentials for silica and silica-based cationic bilayers. Size distribution 
and zeta-potential (ζ) for 0.1 mg/ml silica, dispersion of 1 mM DODAB bilayer fragments and silica/DODAB particles prepared 
from 0.1 mg/ml silica and 0.05 mM DODAB. The intervening medium was 1 mM NaCl, pH 6.3 (A-C) or 5 mM Tris.HCl, pH 7.4 
(D-F). Measurements were performed, after 1 h interaction. In each subfigure, mean zeta-potential and diameter ± SE are 
quoted.BMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
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BSA adsorption onto the particle as detected from the
small area occupied per protein on the silica/DODAB sur-
face, about 3 nm2 (Table 2). It was previously reported by
us that BSA maximal adsorption onto supported DODAB
bilayers deposited on polystyrene sulfate microspheres
with 1 mM NaCl, pH 6.3 as the intervening medium was
also consistent with deposition of an end-on BSA mono-
molecular layer [24]. This agreement for different sup-
porting particles reconfirms not only DODAB bilayer
deposition on silica but also suggests the preferential end-
Low levels of maximal BSA adsorption onto bare silica Figure 3
Low levels of maximal BSA adsorption onto bare silica. BSA adsorption isotherms onto bare SiO2 particles in two dif-
ferent media: 1 mM NaCl, pH 6.3 or 5 mM Tris.HCl, pH 7.4. Open and filled circles refer to two independent experiments 
with each mixture evaluated in duplicate. Interaction between silica particles and protein took place for 1 h at 25°C. Final silica 
concentration is 0.1 mg/ml. BSA adsorption was expressed either as adsorbed BSA concentration in mg/ml (A and C) or as 
number of BSA molecules adsorbed per m2 silica (B and D).BMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
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on mode of BSA adsorption on DODAB bilayer at pH 6.3
and 1 mM NaCl.
Size distributions for BSA aggregates, silica/DODAB and
silica/DODAB/BSA particles are on Figure 5 and Figure 6
for dispersions in 1 mM NaCl, pH 6.3 and in 5 mM
Tris.HCl, pH 7.4, respectively. Interestingly enough,
increasing BSA concentration from 5 up to 30 μg/ml, col-
loid stability rapidly decreased for the latter environment
yielding aggregates with ca. 2.5 μm mean diameter and
High levels of maximal BSA adsorption onto silica-based cationic bilayers Figure 4
High levels of maximal BSA adsorption onto silica-based cationic bilayers. BSA adsorption isotherms onto silica/
DODAB particles in two different media. 1 mM NaCl, pH 6.3 or 5 mM Tris.HCl, pH 7.4. Open and filled circles refer to two 
independent experiments with each mixture evaluated in duplicate. Interaction between silica/DODAB particles and protein 
took place for 1 h at 25°C. Final silica and DODAB concentrations are 0.1 mg/ml and 0.05 mM, respectively. BSA adsorption 
was expressed as adsorbed BSA concentration in mg/ml (A and C) or as number of BSA molecules adsorbed per m2 silica (B 
and D).BMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
Page 8 of 19
(page number not for citation purposes)
BSA adsorption in 1 mM NaCl pH 6.3 affects silica/DODAB particle size and zeta-potential Figure 5
BSA adsorption in 1 mM NaCl pH 6.3 affects silica/DODAB particle size and zeta-potential. Size distribution and 
zeta-potential (ζ) for dispersions in 1 mM NaCl at pH 6.3. In (A), 500 μg/ml BSA. In (B), 0.1 mg/ml silica and 0.05 mM DODAB 
BF dispersion. From C to E, 0.1 mg/ml silica, 0.05 mM DODAB BF dispersion and BSA at 0.005 (C), 0.020 (D) and 0.030 mg/ml 
(E). Interaction between components in the mixtures took place over 1 h before measurements. In each subfigure, mean zeta-
potential and diameter ± SE are quoted.BMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
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BSA adsorption in 5 mM Tris.HCl, pH 7.4 affects silica/DODAB particle size and zeta-potential Figure 6
BSA adsorption in 5 mM Tris.HCl, pH 7.4 affects silica/DODAB particle size and zeta-potential. Size distribution 
and zeta-potential (ζ) for dispersions in 5 mM Tris.HCl, pH 7.4. In (A), 500 μg/ml BSA. In (B), 0.1 mg/ml silica and 0.05 mM 
DODAB BF dispersion. From C to E, 0.1 mg/ml silica, 0.05 mM DODAB BF dispersion and BSA at 0.005 (C), 0.02 (D) and 0.03 
mg/ml (E). Interaction between components in the mixtures took place over 1 h before measurements. In each subfigure, mean 
zeta-potential and diameter ± SE are quoted.BMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
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zeta-potentials close to zero (Figure 6E). The moderate
electrostatic attraction in 1 mM NaCl, pH 6.3 produced
higher colloid stability for silica/DODAB/BSA assemblies
given their positive charge even at the largest BSA concen-
tration (30 μg/ml) (Figure 5E). However, we privileged
the largest adsorbed amount of BSA obtained in Tris.HCl,
pH 7.4 for testing immune response.
Silica-based cationic bilayers for induction of humoral 
immune response
Vaccines based on recombinant protein antigens require
an adjuvant to elicit an immune response [39]. The most
popular, widely used and the only currently FDA-
approved adjuvant class in the USA is represented by alu-
minum salts [40]. Among these, aluminum hydroxide has
a point of zero charge at pH 9–11 so that below this range,
particles are positively charged [40]. For the sake of com-
parison, size distributions and zeta-potentials were
obtained under similar conditions both for aluminum
hydroxide and for silica/DODAB particles (Figure 7). Alu-
minum hydroxide presents a low colloid stability in the
presence of BSA as depicted from the large mean particle
sizes obtained both for positively or negatively charged
final assemblies with BSA. The comparison with silica/
DODAB data in Figures 5 and 6, clearly points out the ade-
quacy of the silica-based supported cationic bilayers as
more stable adjuvants from the point of view of colloid
stability.
The immunoadjuvant effect of silica-based supported cat-
ionic bilayers was evaluated as compared to controls both
from the point of view of IgG antibody production and
cellular immune response as detected from delayed-type
hypersensitivity (DTH) reaction [30] in mice after immu-
nization and challenge. Silica/BSA, DODAB/BSA or silica/
DODAB/BSA induce weak IgG production that can be
ascribed to nonspecific antibodies given the 1:2 serum
dilution employed (Figure 8A). Similarly, the 1:50 serum
dilution employed to obtain IgG production elicited by
silica/DODAB/18 kDa-hsp revealed a weak humoral
response against this antigen (Figure 8B). Interestingly
enough, there is no difference between silica/DODAB/
BSA induces extensive alum aggregation strongly affecting its size distribution and zeta-potential Figure 7
BSA induces extensive alum aggregation strongly affecting its size distribution and zeta-potential. Size distribu-
tion and zeta-potential (ζ) for Al(OH3) (A and C) or Al(OH3)/BSA dispersions (B and D) at 0.1 mg/ml Al(OH3), 1 mM NaCl, 
pH 6.3 (A and B) or 5 mM Tris.HCl, pH 7.4 (C and D).BMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
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Suitability of the silica/DODAB/antigen system to induce IgG response Figure 8
Suitability of the silica/DODAB/antigen system to induce IgG response. Humoral immune response to albumin and 
18 kDa-hsp presented to the immune system via different systems. In A, absorbance at 492 nm as function of time (in days) 
after immunizing mice (n = 8/group) with 0.2 ml of 5 mM Tris/HCl (pH 7.4) solution containing: 10 μg of BSA or 0.02 mg silica 
or silica/DODAB (0.02 mg silica/0.01 mM DODAB) or silica/DODAB/BSA (0.02 mg silica/0.01 mM DODAB/10 μg of BSA) or 
DODAB/BSA (0.02 mM DODAB/10 μg of BSA). Animals were immunized on the abdomen at day zero, at two separate sites 
and bled through the opthalmic plexus at days 24 and 36. IgG antibodies quantification was performed by ELISA. Serum dilution 
was 1:50. (*), significant at P ≤  0.05. In B, absorbance at 405 nm as function of time (in days) after immunizing mice (n = 5/group) 
with: 0.3 mL of 5 mM Tris/HCl (pH 7.4) solution containing 15 μg of 18 kDa-hsp M. leprae, or 0.03 mg silica or silica/DODAB 
(0.03 mg silica/0.015 mM DODAB BF), or silica/DODAB/18 kDa-hsp M. leprae (0.03 mg silica/0.015 mM DODAB/15 μg of 18 
kDa-hsp M. leprae), or Al(OH)3/18 kDa-hsp M. leprae (0.03 mg Al(OH)3/15 μg of 18 kDa-hsp M. leprae); or immunized with: 0.3 
mL of 1 mM NaCl (pH 6.3) solution containing 15 μg of 18 kDa-hsp M. leprae/0.03 mM DODAB BF. Animals were immunized 
on the abdomen at two separate sites at day zero, and an identical booster dose was given on day 15. Animals were bled 
through the opthalmic plexus at days 14, 28 and 84. IgG antibodies quantification was performed by ELISA. Serum dilution was 
1:2. Naïve mice were considered to be those injected with buffer solutions.BMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
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antigen and DODAB/antigen in terms of antibody
responses in the case of 18 kDa-hsp (Figure 8B). We have
recently explored this to systematically study the interest-
ing property of DODAB bilayer fragments as antigen
nanocarriers by themselves. They are also able to induce
good cellular immune responses at very low DODAB con-
centrations (unpublished results). The absorbance values
in Figure 8 are very low and within the range of nonspe-
cific responses to both antigens and might be related to
the antigen preference for self-aggregation in solution
instead of adsorption onto the particles as depicted from
the large sizes of proteic aggregates in solution (Table 1).
The immune responses to the recombinant 18 kDa-hsp
from Mycobacterium leprae were studied in different pres-
entations: free, copolymerized with bovine serum albu-
min in aggregates (18 kDa-hsp-BSA), and either surface
linked to liposomes or entrapped into liposomes [41].
Measuring the antibody production of immunized genet-
ically selected mice has compared the adjuvant effects of
liposomes and proteic copolymer. Among the two lipo-
some preparations, the strongest response was obtained
with the surface-exposed antigen-liposomes[41].
Table 3 shows the % footpad swelling for control mice in
comparison to those immunized with DODAB BF carry-
ing BSA or silica/DODAB/BSA. Although BSA is a poor
antigen regarding elicitation of cellular immune response
due to homology of structure with mice serum albumin,
the silica/DODAB/BSA particulate was so efficient that a
small but significant DTH response could be detected
(Table 3). On the other hand, 18 kDa-hsp was previously
shown to be a potent immune modulator in conjunction
with DODAB large vesicles for DTH response [29]. There-
fore, in the next section, 18 kDa-hsp immobilization and
presentation by silica/DODAB particles is described.
Silica-based cationic bilayers for induction of cellular 
immune response
The adsorption of 18 kDa-hsp onto bare silica or onto sil-
ica/DODAB particles was quantitatively evaluated over a
range of 18 kDa-hsp concentrations in the mixtures (Fig-
ure 9). It was interesting to notice the distinctive shape of
adsorption isotherms for both particulate systems:
whereas the cationic particulate produced adsorption of
high affinity leading to a plateau maximum (Figure 9A
and Figure 9B), bare silica changed the adsorption curve
to a typical competitive adsorption profile with protein-
protein interaction inducing protein desorption from sil-
ica and leading to null adsorption over the high protein
concentration regimen (Figure 9C and Figure 9D). This
result emphasizes the importance of cationic character of
the particulate for maintaining antigen adsorption on par-
ticles.
The 18 kDa-hsp is similar to BSA in the sense that it tends
to form large aggregates in water solution (Figure 10). In
Figure 10A, this aggregation is characterized at 0.5 mg/ml
of 18 kDa-hsp concentration indicating negatively
charged aggregates (-43 mV of zeta-potential) with 360
nm of mean hydrodynamic diameter. Adding protein at
0.005 mg/ml of final 18 kDa-hsp concentration to the sil-
ica/DODAB particles produced a positively charged par-
Table 3: Percentage footpad swelling (%fs) (delayed-type hypersensitivity reaction) to BSA or 18 kDa-hsp M. leprae antigens supported 
on DODAB-covered silica particles, or complexed with Al(OH3).
Systems for sensitization Ag/dose for sensitization (μg/mouse) Elicitation (μg/mouse)(i)
BSA 18 kDa-hsp M. leprae
44 0 3 3 0
% footpad swelling ± SEM
Silica/DODAB(ii) -2  ±  2 2  ±  2 - -
BSA 10 2 ± 2 2 ± 2 - -
Silica/BSA(ii) 10 3 ± 2 2 ± 2 - -
DODAB BF(iii)/BSA 10 3 ± 2 2 ± 2 - -
Silica/DODAB/BSA(ii) 10 11 ± 2(iv) 14 ± 4(iv) --
18 kDa-hsp M. leprae 15 - - 4 ± 2 10 ± 2
DODAB BF(iii)/18 kDa-hsp 15 56 ± 8(iv), (v) 95 ± 16(iv), (v)
Silica/DODAB/18 kDa-hsp(ii) 15 - - 60 ± 7(iv), (v) 89 ± 8(iv), (v)
Al(OH)3/18 kDa-hsp(ii) 15 - - 18 ± 4(iv) 33 ± 1(iv)
(i) Animals were sensitized with different systems and footpad swelling was elicited on the 5th day pos-immunization.
(ii) Silica at final concentration of 0.1 mg/ml; DODAB at final concentration of 0.05 mM. Al(OH)3 at final concentration of 0.1 mg/ml.
(iii) [DODAB] = 0.1 mM.
(iv) P < 0.05, compared to animals that were BSA or 18 kDa-hsp M. leprae-pretreated and received the same elicitation dose.
(v) P < 0.05, compared to animals that were Al(OH3)/18 kDa-hsp-pretreated and received the same elicitation dose.BMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
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ticulate with 411 nm of mean diameter and zeta-potential
of 24 mV (Figure 10D). Increasing final 18 kDa-hsp by ten
times up to a final concentration of 0.05 mg/ml led to
large colloidal instability and mean diameter (2132 nm)
due to occurrence of a zeta-potential close to zero (-2 mV)
(Figure 10E). Therefore, for assaying the DTH immune
response, the protein concentration chosen was interme-
diary at 0.015 mg/ml (Table 3). The DTH response
induced by silica/DODAB/18 kDa-hsp after sensitizing
the mice with 0.015 mg/ml 18 kDa-hsp was excellent and
higher than the one elicited by alum adjuvant under anal-
ogous conditions (Table 3). In agreement with the DTH
response, cytokines production, especially INF-γ, revealed
the superior character of the silica/DODAB adjuvant in
comparison to alum (Figure 11). Therefore, the silica/
DODAB/antigen system is prone to be used as a biocom-
patible cationic adjuvant for antigen presentation and
vaccine design. Much larger biomimetic crystals com-
posed of hydroxyapatite or urate with several micrometers
of mean diameter and diverse crystal shapes revealed their
Poor maximal adsorption of antigen on bare silica against sustained maximal adsorption onto cationized silica Figure 9
Poor maximal adsorption of antigen on bare silica against sustained maximal adsorption onto cationized silica. 
18 kDa-hsp adsorption onto SiO2/DODAB particles (A-B) or bare SiO2 particles (C-D) in 5 mM Tris.HCl, pH 7.4. Interaction 
between particles and protein took place for 1 h at 25°C. Final silica and DODAB concentrations are 0.1 mg/ml and 0.05 mM, 
respectively. 18 kDa-hsp M. leprae adsorption was expressed either as adsorbed 18 kDa-hsp M. leprae concentration in mg/ml 
(A and C) or as number of 18 kDa-hsp M. leprae molecules adsorbed per m2 silica (B and D).BMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
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robust effect on the expression of CD11b, MHC-class II
and CD 86 on peritoneal macrophages systems [42]. The
system described in this work is also expected to provide
a variety of shapes since silica particles are forming aggre-
gates from primary particles of 50 nm mean diameter.
Indeed manipulation of the physico-chemical features of
the particulates provides means of controlling the innate
immune response.
Conclusion
Supported cationic bilayers built on silica can effectively
adsorb antigens to elicit superior immune responses in
vivo. They can be prepared from a tiny amount of cationic
and inexpensive synthetic lipid, just enough for covering
silica particles with a cationic layer. The main advantage
of this adjuvant system is precisely this low amount of
cytotoxic cationic lipid employed in comparison to cati-
onic liposomes usually used over a range of millimolar
concentrations. Regarding physical properties, silica/
DODAB particulates are less polydisperse than alum
allowing better antigen presentation and eliciting superior
cellular immune responses. Therefore, cationized silica is
a biocompatible, inexpensive, easily prepared and possi-
bly general immunoadjuvant for antigen presentation
which displays higher colloid stability than alum and bet-
ter performance regarding cellular immune responses.
Methods
Lipids, silica particles and antigen
Dioctadecyldimethylammonium bromide (DODAB)
99.9% pure was obtained from Sigma-Aldrich (St Louis,
MO, USA). Silica (Aerosil OX-50) with a 50 nm mean
diameter from transmission electron microscopy and
nominally, 26 m2/g specific surface area was a gift from
Degussa (Degussa Co.). A stock silica dispersion at 4 mg/
m l  w a s  p r e p a r e d  i n  1  m M  N a C l  ( p H  6 . 3 )  o r  5  m M
Tris.HCl (pH 7.4) solutions, which provide adequate
ionic strengths to assemble DODAB as a single bilayer
onto particles [15]. Bovine serum albumin (BSA) was pur-
chased from Sigma-Aldrich, and prepared as a 1 mg/ml
stock solution in 1 mM NaCl (pH 6.3) or 5 mM Tris.HCl
5 mM (pH 7.4) and stored in a freezer in 1 ml aliquots for
quick use. Recombinant 18 kDa-hsp Mycobacterium leprae
protein (18 kDa-hsp) was prepared as previously
described [28] and diluted in 1 mM NaCl (pH 6.3) or 5
mM Tris.HCl (pH 7.3) to obtain a stock solution at 2 mg/
ml. 18 kDa-hsp concentration was determined spectro-
photometrically measuring the absorbance at λ = 230 nm,
using a standard curve (5 – 160 μg/ml) of 18 kDa-hsp, as
previously described [43]. BSA concentration was deter-
mined by a protein microassay, based on the method of
Lowry [44], using a standard curve (10 – 100 μg/ml) of
BSA. Aluminium hydroxide adjuvant Al(OH3) was
obtained from Merial do Brasil (Merial Ltda.). NaCl,
Trizma base, and all other reagents were analytical grade.
Water was Milli-Q quality.
Preparation of lipidic dispersions and analytical 
determination of lipid concentration
Small DODAB bilayer fragments were prepared by sonica-
tion with titanium macrotip probe in 1 mM NaCl (pH
6.3) or 5 mM Tris.HCl (pH 7.4) water solution at ca. 2.0
mM DODAB (nominal potency, 80 W/15 min of sonica-
tion time) as previously described [45]. Following sonica-
tion, the solutions were centrifuged (10.000 g/15°C/40
min) to eliminate the titanium ejected from the tip. Mean
size and ζ-potential for the DODAB dispersions are
shown in Table 1. The DODAB concentration was deter-
mined spectrophotometrically from Orange G/DODAB
solubilization in neutral micelles [46] or from halide
microtitration [47]. The silica powder was routinely dis-
persed by sonication with a titanium tip (85 W/10 min)
in 1 mM NaCl (pH 6.5) or 5 mM Tris.HCl (pH 7.5). Tita-
nium particles ejected from the tip were allowed to pellet
for 1 h before the silica dispersion was withdrawn from
the supernatant for further use.
Preparation of silica/DODAB and silica/DODAB/protein 
assemblies
Stock dispersions of silica particles at 4 mg/ml and stock
DODAB bilayer fragments BF dispersions at 2.0 mM
DODAB were dispersed either in 1 mM NaCl (pH 6.3) or
in 5 mM Tris.HCl (pH 7.4) and diluted to the final desired
concentration using this same solution of NaCl or
Tris.HCl. First, to obtain lipid-covered silica particles, sil-
ica, at 0.1 mg/ml final concentration, and oppositely
charged DODAB BF solutions ranging from 0.1 μM to 1
mM, interacted for 1 h/25°C. DODAB final co ncentra-
tion for producing the assemblies was selected as 50 μM at
0.1 mg/ml of silica since this concentration is the one
required to cover each silica particle with a DODAB
bilayer [15]. In fact, experimentally it is shown in Figure 1
that from this concentration cationic particles are indeed
obtained. In a second experimental step, the stock BSA or
18 kDa-hsp solutions were used to obtain final protein
concentrations ranging from 5 to 50 μg/ml after addition
to the silica/DODAB mixture, for 1 h/25°C interaction.
Thereafter, sizes, zeta-potentials, and polydispersities
were determined. Considering the total surface area of 2.6
× 10-3 m2 the selected DODAB concentration of 0.05 mM
was more than sufficient to produce bilayer-covered parti-
cles.
Determination of average zeta-diameter and zeta-
potential for particles, bilayer fragments, or mixtures of 
both
Particle size (mean diameter Dz), size distribution, poly-
dispersity and zeta-potential (ζ) in the presence or
absence of silica, DODAB and BSA or 18 kDa-hsp were
determined using the ZetaPlus-ZetaPotential Analyzer
(Brookhaven Instruments Corporation, Holtsville, NY),
which was equipped with a 677 nm laser and dynamic
light scattering (PCS) at 90° for particle sizing. Mean dBMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
Page 15 of 19
(page number not for citation purposes)
Antigen adsorption induces silica/DODAB aggregation Figure 10
Antigen adsorption induces silica/DODAB aggregation. Size distribution and zeta-potential (ζ) for dispersions in 5 mM 
Tris.HCl, pH 7.4. In (A), 500 μg/ml 18 kDa-hsp M. leprae. In (B), 0.1 mg/ml silica. In (C), 0.1 mg/ml silica and 0.05 mM DODAB 
BF dispersion. From D to E, 0.1 mg/ml silica, 0.05 mM DODAB BF dispersion and 18 kDa-hsp M. leprae at 0.005 (D), and 0.05 
mg/ml (E). Interaction between components in the mixtures took place over 1 h before measurements. In each subfigure, mean 
zeta-potential and diameter ± SE are quoted.BMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
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iameters were obtained by fitting data to log-normal size
distributions which do not discriminate between one,
two, or more different populations and considers always
all scattering particles as belonging to one single Gaussian
population. On the other hand, for the size distribution
data, fitting was performed by the apparatus software
using the non-negatively constrained least squares
(NNLS) algorithm, which is a model independent tech-
nique allowing to achieve multimodal distributions [48].
ζ was determined from electrophoretic mobility μ in 1
mM NaCl and the Smoluchowski's equation: ζ = μη /ε,
where η  is the medium viscosity and ε the medium dielec-
tric constant.
Determination of BSA and 18 kDa-hsp adsorption 
isotherms
BSA adsorption isotherms on silica alone, in 1 mM NaCl
(pH 6.3) or 5 mM Tris.HCl (pH 7.4), were obtained by
mixing 0.05 ml of silica solution (0.4 mg/ml) with 0.15
ml of the appropriate BSA dilution in 1 mM NaCl or 5
mM Tris.HCl. For BSA adsorption onto silica/DODAB
particles, prior to protein addition, 0.05 ml of silica solu-
tion was allowed to interact for 1 hour with 0.05 ml of a
0.2 mM DODAB BF dispersion; thereafter, BSA solution
was added to yield a final volume of 0.2 ml. Final concen-
tration of BSA in the assays ranged from 0 – 150 μg/ml, at
a fixed concentration of 0.1 mg silica/ml and 0.05 mM
DODAB BF. After 1 h silica/BSA or silica/DODAB/BSA
interaction at 25°C, a clear supernatant was obtained by
centrifugation at 15,000 rpm for 1.5 h. The concentration
of protein in the supernatant was determined by Lowry
microassay using a standard curve prepared from 10 – 100
μg/ml BSA [38]. The method is sensitive over a protein
concentration range of 0.005–0.100 mg/ml. A microplate
reader equipped with a 655 nm filter (Ultramark, Model
550 Bio-Rad, Hercules, CA, USA) was used for absorbance
measurement.
18 kDa-hsp adsorption isotherms on silica alone, in 5 mM
Tris.HCl (pH 7.4), were obtained by mixing 0.025 ml of
stock silica dispersion (4 mg/ml) with 0.975 ml of the
appropriate 18 kDa-hsp dilution in 5 mM Tris.HCl. For 18
kDa-hsp adsorption onto silica/DODAB particles, prior to
protein addition, 0.025 ml of stock silica dispersion was
allowed to interact for 1 hour with 0.025 ml of a 2 mM
DODAB BF dispersion; thereafter, 18 kDa-hsp solution
was added to yield a final volume of 1 ml. Final concen-
tration of 18 kDa-hsp in the assays ranged from 0 – 120
μg/ml, at a fixed concentration of 0.1 mg silica/ml and
0.05 mM DODAB BF. After 1 h silica/18 kDa-hsp or silica/
DODAB/18 kDa-hsp interaction at 25°C, a clear superna-
tant was obtained by centrifugation at 15,000 rpm for 1.5
h. The concentration of protein in the supernatant was
determined spectrophotometrically by measuring the
absorbance at λ = 230 nm, using a standard curve (5 – 160
Suitability of the silica/DODAB/antigen system to induce  improved cytokines production Figure 11
Suitability of the silica/DODAB/antigen system to 
induce improved cytokines production. Cytokine 
responses generated by SiO2/DODAB/18 kDa-hsp and 
Al(OH)3/18 kDa-hsp. Release of IL-10 (A), IL-12 (B), IL-13 
(C) and IFN-γ (D) from inguinal and periaortic lymph node 
cells isolated from BALB/c mice immunized with 15 μg of 18 
kDa-hsp M. leprae administered in silica/DODAB or 
Al(OH)3. Lymph node cells were isolated six days after 
immunization and re-stimulated in vitro with 250 μg/ml of 18 
kDa-hsp or 2.5 μg/mL of ConA for 48 hours. The cytokine 
levels were measured by sandwich kit enzyme-linked immu-
nosorbent assay (ELISA) as described in materials and meth-
ods. The limit of detection was 156 pg/mL for IL-10 and IL-
12, and 78 pg/mL for IL-13 and IFN-γ respectively.BMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
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μg/ml) of 18 kDa-hsp, as previously described [37]. A
spectrophotometer Hitachi U-2000 was used for absorb-
ance measurement.
For both proteins, the amount of adsorbed protein was
determined by the difference between the total protein
added and the amount of protein recovered in the super-
natant.
Adsorption was expressed as the number of molecules
adsorbed per square meter silica. Curves were fitted using
cubic polynomial regression. Wherever possible, the
Langmuir model was employed for isotherms lineariza-
tion and determination of adsorption constants such as
affinity constant (K, in M-1) and maximal adsorption (in
number of molecules per m2 silica) [49].
Subcutaneous immunization, assay for delayed-type 
hypersensitivity (DTH) and antigen-specific ELISA
BALB/c female mice 8–12-week old were purchased from
the University of São Paulo, São Paulo, Brazil. Six groups
of 8 – 10 female mice were challenged subcutaneously (s.
c.) in the abdomen at two separate sites. Total volume
injected in each site was 0.1 or 0.15 mL for BSA or 18 kDa-
hsp, respectively. The dispersion injected contained
either: (a) 10 μg BSA or 15 μg 18 kDa-hsp in 5 mM
TrisHCl (pH 7.4); or (b) 10 μg BSA or 15 μg 18 kDa-hsp
in 1 mM NaCl and 0.1 mM DODAB; or (c) 10 μg BSA or
15 μg 18 kDa-hsp in 0.1 mg silica/mL, 5 mM Tris.HCl; or
(d) 10 μg BSA or 15 μg 18 kDa-hsp in silica/DODAB (0.1
mg mL-1/0.05 mM) in 5 mM Tris.HCl; or (e) 0.1 mg silica/
mL in 5 mM Tris.HCl. For DTH evaluation, the footpad
swelling test was carried out essentially as previously
described [9,26,27]. On the fifth day post subcutaneous
immunization, pre-immunized mice with BSA, 18 kDa-
hsp, DODAB/BSA, DODAB/18 kDa-hsp, silica/BSA, sil-
ica/18 kDa-hsp, silica/DODAB/BSA, silica/DODAB/18
kDa-hsp or silica alone, were challenged in the left-hind
footpad with a total elicitation dose of 4 or 40 μg BSA or
3 or 30 μg 18 kDa-hsp in 50 μL Tris.HCl 5 mM, respec-
tively. Footpad swelling was measured 24 h later with a
Mitutoyo engineering micrometer. Depending on the age
of the animals, the thickness of uninjected hind footpad
varied from 1.60 to 1.70 mm. Percentage footpad swelling
(%fs) is calculated according to the formula below with
results expressed as %fs ± standard error of the mean
(SEM).
%fs = 100 [(left hind footpad thickness) - (right hind foot-
pad thickness)]/(mean thickness uninjected left hind 
footpad).
For evaluation of humoral immune response, the same
groups previously immunized and challenged with BSA
above were bled through the ophthalmic plexus in days
24 and 36, after immunization. The sera obtained were
analyzed by ELISA. Each well of 96-well ELISA polystyrene
high binding plates (Costar Corning Inc., Cambridge,
Mass.) was coated with 100 μL of BSA (final concentration
of 0.05 μg/well) in 0.5 M carbonate-bicarbonate buffer
(pH 9.6) for 18 h in an humidified chamber at 4°C. The
wells were blocked for 1 h with 5% milk in PBS contain-
ing 0.05% Tween 20 (PBS/T), and then incubated for one
hour with serum samples diluted 1:50 or 1:200, for spe-
cific IgG antibody quantitation. In each well, 100 μL of
goat anti-mouse IgG peroxidase-conjugate (Sigma)
diluted 1:3000 was added and plates were incubated for 1
h. After each incubation step, the plates were washed
using an automatic washer, with four cycles of PBS/T.
Ortho-phenylenediamine (1 mg/mL) (Sigma) and H2O2
(1 μL/mL) diluted in 0.2 M citrate buffer (pH 5.0) were
added (in the dark) as chromogenic substrate and plates
were incubated for 10 min. The reactions were stopped by
adding 100 μL of 2 M H2SO4. Color intensity was quanti-
fied using an ELISA plate reader (Diagnostics Pasteur,
Strassburg-Schiltigheim, France) at 492 nm. All incuba-
tions were carried out at 37°C. Antibody titers remained
below 1/100 dilution, meaning that the dilution is not
high enough to discriminate specific and non specific
antibodies against BSA. Serum titration included a serum
from naïve mice and a serum from mice immunised with
a non relevant antigen towards induction of humoral
immune response, namely, hsp-18 kDa protein itself.
For evaluation of humoral immune response against 18
kDa-hsp, the same groups previously immunized and
challenged with 18 kDa-hsp above were bled through the
ophthalmic plexus in days 14, 28, and 84 after immuniza-
tion. The sera obtained were analyzed by ELISA. Each well
of 96-well ELISA polystyrene maxisorpt plates (Maxisorp,
Nunc) was coated with 100 μL of 18 kDa-hsp (final con-
centration of 40 μg/well) in 0.5 M carbonate-bicarbonate
buffer (pH 9.6) for 18 h in an humidified chamber at 4°C.
The wells were blocked for 1 h with 5% milk in PBS con-
taining 0.05% Tween 20 (PBS/T), and then incubated for
one hour with serum samples diluted 1:2, for specific IgG
antibody quantitation. In each well, 100 μL of goat anti-
mouse IgG peroxidase-conjugate (Sigma) diluted 1:1000
was added and plates were incubated for 1 h. After each
incubation step, the plates were washed using an auto-
matic washer, with four cycles of PBS/T. Ortho-phenylen-
ediamine (1 mg/mL) (Sigma) and H2O2  (1  μL/mL)
diluted in 0.2 M citrate buffer (pH 5.0) were added (in the
dark) as chromogenic substrate and plates were incubated
for 10 min. The reactions were stopped by adding 100 μL
of 2 M H2SO4. Color intensity was quantified using an
ELISA plate reader A microplate reader equipped with a
405 nm filter (Ultramark, Model 550 Bio-Rad, Hercules,
CA, USA) was used for absorbance measurement. All incu-
bations were carried out at 37°C.BMC Biotechnology 2009, 9:5 http://www.biomedcentral.com/1472-6750/9/5
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Cell culture and cytokine analysis
Six days after immunization, cell suspensions from
inguinal and periaortic lymph nodes (LN) of 5 mice were
prepared in RPMI 1640 (GIBCO) supplemented with 10
mM HEPES, 50 μM 2-Mercaptoethanol, 216 mg L-
glutamine/L and 5 % FCS (GIBCO). The cell suspensions
(8 × 106 cells) were distributed into tissue culture 24-wells
plates (Costar) and incubated with medium containing
250 μg/mL of 18 kDa-hsp M. leprae in a humidified CO2
incubator for 48 hours. Wells containing medium only or
2.5 μg/mL of ConA (Sigma Aldrich) were included in all
experiments as negative and positive controls, respec-
tively. After this time, the plates were centrifuged for 8
minutes at 500 × g and the supernatants collected for
cytokine content. The levels of cytokines (IL-10, IL12, IL-
13 and IFN-γ) in the supernatants were assayed by sand-
wich kit enzyme-linked immunosorbent assay (ELISA),
using the following monoclonal antibodies: MAB417 and
biotinylated-BAF417 for IL-10; MAB419 and biotinylated-
BAF419 for IL-12; MAB413 and biotinylated-BAF413 for
IL-13; and XMG 1.2 and biotinylated-AN18 for IFN-γ,
according to the manufacturer's suggestion (R&D Systems
– Minneapolis, MN). Binding of the biotinylated antibod-
ies was determined using the streptavidin-peroxidase con-
jugate (Sigma) and TMB (3,3',5,5'-Tetramethylbenzidine;
Sigma) solution in citrate buffer plus Hydrogen peroxide.
The plates were read (450 nm) in an automated ELISA
reader (Dynatech MR5000). Samples were quantified by
comparison with standard curves of purified recombinant
cytokines and the values expressed as ng/mL. The limit of
detection was 156 pg/mL for IL-10 and IL-12, and 78 pg/
mL for IL-13 and IFN-γ respectively.
Statistical analysis
ANOVA one-way multiple comparison tests and the
Kruskal-Wallis non-parametric test were used when
needed. A P value of ≤  0.05 was considered significant.
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